Advertisement

Meta-Analysis of Long-Term Clinical Outcomes of Everolimus-Eluting Stents

      The superiority of everolimus-eluting stents (EES) over sirolimus-eluting stents (SES) for long-term clinical outcomes has not been yet firmly established. We conducted a systematic review and a meta-analysis of randomized controlled trials (RCTs) comparing EES directly with SES using the longest available follow-up data. We searched PubMed, the Cochrane database, and ClinicalTrials.gov for RCTs comparing outcomes between EES and SES and identified 13,434 randomly assigned patients from 14 RCTs. EES was associated with significantly lower risks than SES for definite stent thrombosis (ST), definite/probable ST, target-lesion revascularization (TLR), and major adverse cardiac events (MACE). The risks for all-cause death and myocardial infarction were similar between EES and SES. By the stratified analysis according to the timing after stent implantation, the favorable trend of EES relative to SES for ST, TLR, and MACE was consistently observed both within and beyond 1 year. The lower risk of EES relative to SES for MACE beyond 1 year was statistically significant (pooled odds ratio 0.77, 95% confidence interval 0.61 to 0.96, p = 0.02). In conclusion, the current meta-analysis of 14 RCTs directly comparing EES with SES suggested that EES provided improvement in both safety and efficacy; EES compared with SES was associated with significantly lower risk for definite ST, definite/probable ST, TLR, and MACE. The direction and magnitude of the effect beyond 1 year were comparable with those observed within 1 year.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • de Waha A.
        • Dibra A.
        • Byrne R.A.
        • Ndrepepa G.
        • Mehilli J.
        • Fusaro M.
        • Laugwitz K.L.
        • Massberg S.
        • Schomig A.
        • Kastrati A.
        Everolimus-eluting versus sirolimus-eluting stents: a meta-analysis of randomized trials.
        Circ Cardiovasc Interv. 2011; 4: 371-377
        • de Waha A.
        • Cassese S.
        • Park D.W.
        • Burzotta F.
        • Byrne R.A.
        • Tada T.
        • King L.A.
        • Park S.J.
        • Schomig A.
        • Kastrati A.
        Everolimus-eluting versus sirolimus-eluting stents: an updated meta-analysis of randomized trials.
        Clin Res Cardiol. 2012; 101: 461-467
        • Park K.W.
        • Kang S.H.
        • Velders M.A.
        • Shin D.H.
        • Hahn S.
        • Lim W.H.
        • Yang H.M.
        • Lee H.Y.
        • Van Boven A.J.
        • Hofma S.H.
        • Kang H.J.
        • Koo B.K.
        • Oh B.H.
        • Park Y.B.
        • Kandzari D.E.
        • Kim H.S.
        Safety and efficacy of everolimus- versus sirolimus-eluting stents: a systematic review and meta-analysis of 11 randomized trials.
        Am Heart J. 2013; 165: 241-250 e4
        • Kimura T.
        • Morimoto T.
        • Nakagawa Y.
        • Kawai K.
        • Miyazaki S.
        • Muramatsu T.
        • Shiode N.
        • Namura M.
        • Sone T.
        • Oshima S.
        • Nishikawa H.
        • Hiasa Y.
        • Hayashi Y.
        • Nobuyoshi M.
        • Mitudo K.
        • j-Cypher Registry Investigators
        Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry.
        Circulation. 2012; 125: 584-591
      1. Higgins J. Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 (Available at:)
        • Cutlip D.E.
        • Windecker S.
        • Mehran R.
        • Boam A.
        • Cohen D.J.
        • van Es G.A.
        • Steg P.G.
        • Morel M.A.
        • Mauri L.
        • Vranckx P.
        • McFadden E.
        • Lansky A.
        • Hamon M.
        • Krucoff M.W.
        • Serruys P.W.
        • Academic Research C.
        Clinical end points in coronary stent trials: a case for standardized definitions.
        Circulation. 2007; 115: 2344-2351
        • Sakakibara T.
        • Ishii H.
        • Toriyama T.
        • Aoyama T.
        • Takahashi H.
        • Kamoi D.
        • Kawamura Y.
        • Kawashima K.
        • Yoneda K.
        • Amano T.
        • Tanaka M.
        • Yoshikawa D.
        • Hayashi M.
        • Matsubara T.
        • Murohara T.
        Sirolimus-eluting stent vs. everolimus-eluting stent for coronary intervention in patients on chronic hemodialysis.
        Circ J. 2012; 76: 351-355
        • Park D.W.
        • Kim Y.H.
        • Song H.G.
        • Ahn J.M.
        • Kim W.J.
        • Lee J.Y.
        • Kang S.J.
        • Lee S.W.
        • Lee C.W.
        • Park S.W.
        • Yun S.C.
        • Seung K.B.
        • Yang T.H.
        • Lee S.G.
        • Lee J.H.
        • Seong I.W.
        • Cheong S.S.
        • Lee B.K.
        • Lee N.H.
        • Lee S.W.
        • Lee S.W.
        • Lee K.
        • Kim H.S.
        • Jeon D.S.
        • Kim M.K.
        • Nah D.Y.
        • Tahk S.J.
        • Park S.J.
        Comparison of everolimus- and sirolimus-eluting stents in patients with long coronary artery lesions: a randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III) Trial.
        JACC Cardiovasc Interv. 2011; 4: 1096-1103
        • Higgins J.P.
        • Thompson S.G.
        • Deeks J.J.
        • Altman D.G.
        Measuring inconsistency in meta-analyses.
        BMJ (Clinical Res Ed). 2003; 327: 557-560
        • Burzotta F.
        • Trani C.
        • Todaro D.
        • Mariani L.
        • Talarico G.P.
        • Tommasino A.
        • Giammarinaro M.
        • Niccoli G.
        • Porto I.
        • Leone A.M.
        • Mongiardo R.
        • Mazzari M.A.
        • Schiavoni G.
        • Crea F.
        Prospective randomized comparison of sirolimus- or everolimus-eluting stent to treat bifurcated lesions by provisional approach.
        JACC Cardiovasc Interv. 2011; 4: 327-335
        • Pan M.
        • Medina A.
        • Suarez de Lezo J.
        • Romero M.
        • Segura J.
        • Martin P.
        • Suarez de Lezo J.
        • Hernandez E.
        • Mazuelos F.
        • Ojeda S.
        Randomized study comparing everolimus- and sirolimus-eluting stents in patients with bifurcation lesions treated by provisional side-branch stenting.
        Catheter Cardiovasc Interv. 2012; 80: 1165-1170
        • Pan M.
        • Burzotta F.
        • Trani C.
        • Medina A.
        • Suarez de Lezo J.
        • Niccoli G.
        • Romero M.
        • Porto I.
        • Mazuelos F.
        • Leone A.M.
        • Martin P.
        • Coluccia V.
        • Suarez de Lezo J.
        • Ojeda S.
        • Crea F.
        Three-year follow-up of patients with bifurcation lesions treated with sirolimus- or everolimus-eluting stents: SEAside and CORpal Cooperative Study.
        Rev Esp Cardiol. 2014; 67: 787-789
        • Hofma S.H.
        • Brouwer J.
        • Velders M.A.
        • van't Hof A.W.
        • Smits P.C.
        • Quere M.
        • de Vries C.J.
        • van Boven A.J.
        Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial.
        J Am Coll Cardiol. 2012; 60: 381-387
        • Velders M.A.
        • Hofma S.H.
        • Brouwer J.
        • de Vries C.J.
        • Quere M.
        • van Boven A.J.
        Two-year results of an open-label randomized comparison of everolimus-eluting stents and sirolimus-eluting stents.
        PLoS One. 2013; 8: e64424
        • Velders M.A.
        • van Boven A.J.
        • Brouwer J.
        • Smits P.C.
        • van 't Hof A.W.
        • de Vries C.J.
        • Quere M.
        • Hofma S.H.
        Everolimus- and sirolimus-eluting stents in patients with and without ST-segment elevation myocardial infarction.
        Neth Heart J. 2014; 22: 167-173
        • Nakazawa G.
        Stent thrombosis of drug eluting stent: pathological perspective.
        J Cardiol. 2011; 58: 84-91
        • Kimura T.
        • Morimoto T.
        • Kozuma K.
        • Honda Y.
        • Kume T.
        • Aizawa T.
        • Mitsudo K.
        • Miyazaki S.
        • Yamaguchi T.
        • Hiyoshi E.
        • Nishimura E.
        • Isshiki T.
        • Investigators R.
        Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART).
        Circulation. 2010; 122: 52-61
        • Inoue K.
        Pathological perspective of drug-eluting stent thrombosis.
        Thrombosis. 2012; 2012: 219389
        • Holmes Jr., D.R.
        • Kereiakes D.J.
        • Garg S.
        • Serruys P.W.
        • Dehmer G.J.
        • Ellis S.G.
        • Williams D.O.
        • Kimura T.
        • Moliterno D.J.
        Stent thrombosis.
        J Am Coll Cardiol. 2010; 56: 1357-1365
        • Kolandaivelu K.
        • Swaminathan R.
        • Gibson W.J.
        • Kolachalama V.B.
        • Nguyen-Ehrenreich K.L.
        • Giddings V.L.
        • Coleman L.
        • Wong G.K.
        • Edelman E.R.
        Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings.
        Circulation. 2011; 123: 1400-1409
        • Palmerini T.
        • Biondi-Zoccai G.
        • Della Riva D.
        • Stettler C.
        • Sangiorgi D.
        • D'Ascenzo F.
        • Kimura T.
        • Briguori C.
        • Sabate M.
        • Kim H.S.
        • De Waha A.
        • Kedhi E.
        • Smits P.C.
        • Kaiser C.
        • Sardella G.
        • Marullo A.
        • Kirtane A.J.
        • Leon M.B.
        • Stone G.W.
        Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.
        Lancet. 2012; 379: 1393-1402
        • Sabate M.
        • Cequier A.
        • Iniguez A.
        • Serra A.
        • Hernandez-Antolin R.
        • Mainar V.
        • Valgimigli M.
        • Tespili M.
        • den Heijer P.
        • Bethencourt A.
        • Vazquez N.
        • Gomez-Hospital J.A.
        • Baz J.A.
        • Martin-Yuste V.
        • van Geuns R.J.
        • Alfonso F.
        • Bordes P.
        • Tebaldi M.
        • Masotti M.
        • Silvestro A.
        • Backx B.
        • Brugaletta S.
        • van Es G.A.
        • Serruys P.W.
        Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial.
        Lancet. 2012; 380: 1482-1490
        • Otsuka F.
        • Vorpahl M.
        • Nakano M.
        • Foerst J.
        • Newell J.B.
        • Sakakura K.
        • Kutys R.
        • Ladich E.
        • Finn A.V.
        • Kolodgie F.D.
        • Virmani R.
        Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans.
        Circulation. 2014; 129: 211-223
        • Shimamura K.
        • Kubo T.
        • Akasaka T.
        • Kozuma K.
        • Kimura K.
        • Kawamura M.
        • Sumiyoshi T.
        • Ino Y.
        • Yoshiyama M.
        • Sonoda S.
        • Igarashi K.
        • Miyazawa A.
        • Uzui H.
        • Sakanoue Y.
        • Shinke T.
        • Morino Y.
        • Tanabe K.
        • Kadota K.
        • Kimura T.
        Outcomes of everolimus-eluting stent incomplete apposition: a serial optical coherence tomography analysis.
        Eur Heart J Cardiovasc Imaging. 2015; 16: 23-28
        • Mauri L.
        • Kereiakes D.J.
        • Yeh R.W.
        • Driscoll-Shempp P.
        • Cutlip D.E.
        • Steg P.G.
        • Normand S.L.
        • Braunwald E.
        • Wiviott S.D.
        • Cohen D.J.
        • Holmes Jr., D.R.
        • Krucoff M.W.
        • Hermiller J.
        • Dauerman H.L.
        • Simon D.I.
        • Kandzari D.E.
        • Garratt K.N.
        • Lee D.P.
        • Pow T.K.
        • Ver Lee P.
        • Rinaldi M.J.
        • Massaro J.M.
        • Investigators D.S.
        Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
        N Engl J Med. 2014; 371: 2155-2166
        • Moreno R.
        • Garcia E.
        • Teles R.
        • Rumoroso J.R.
        • Cyrne Carvalho H.
        • Goicolea F.J.
        • Moreu J.
        • Mauri J.
        • Sabate M.
        • Mainar V.
        • Patricio L.
        • Valdes M.
        • Fernandez Vazquez F.
        • Sanchez-Recalde A.
        • Galeote G.
        • Jimenez-Valero S.
        • Almeida M.
        • Lopez de Sa E.
        • Calvo L.
        • Plaza I.
        • Lopez-Sendon J.L.
        • Martin J.L.
        Randomized comparison of sirolimus-eluting and everolimus-eluting coronary stents in the treatment of total coronary occlusions: results from the chronic coronary occlusion treated by everolimus-eluting stent randomized trial.
        Circ Cardiovasc Interv. 2013; 6: 21-28
        • Kimura T.
        • Morimoto T.
        • Natsuaki M.
        • Shiomi H.
        • Igarashi K.
        • Kadota K.
        • Tanabe K.
        • Morino Y.
        • Akasaka T.
        • Takatsu Y.
        • Nishikawa H.
        • Yamamoto Y.
        • Nakagawa Y.
        • Hayashi Y.
        • Iwabuchi M.
        • Umeda H.
        • Kawai K.
        • Okada H.
        • Kimura K.
        • Simonton C.A.
        • Kozuma K.
        Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-Eluting Versus Everolimus-Eluting Stent Trial (RESET).
        Circulation. 2012; 126: 1225-1236